Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Deferoxamine infusion during coronary artery bypass grafting ameliorates lipid peroxidation and protects the myocardium against reperfusion injury: immediate and long-term significance.
Paraskevaidis IA, Iliodromitis EK, Vlahakos D, Tsiapras DP, Nikolaidis A, Marathias A, Michalis A, Kremastinos DT. Paraskevaidis IA, et al. Eur Heart J. 2005 Feb;26(3):263-70. doi: 10.1093/eurheartj/ehi028. Epub 2004 Nov 30. Eur Heart J. 2005. PMID: 15618054 Clinical Trial.
Design, synthesis and biological evaluation of cyclic angiotensin II analogues with 3,5 side-chain bridges. Role of C-terminal aromatic residue and ring cluster for activity and implications in the drug design of AT1 non-peptide antagonists.
Roumelioti P, Polevaya L, Zoumpoulakis P, Giatas N, Mutule I, Keivish T, Zoga A, Vlahakos D, Iliodromitis E, Kremastinos D, Grdadolnik SG, Mavromoustakos T, Matsoukas J. Roumelioti P, et al. Bioorg Med Chem Lett. 2002 Sep 16;12(18):2627-33. doi: 10.1016/s0960-894x(02)00474-2. Bioorg Med Chem Lett. 2002. PMID: 12182875
Synthesis and study of a cyclic angiotensin II antagonist analogue reveals the role of pi*--pi* interactions in the C-terminal aromatic residue for agonist activity and its structure resemblance with AT(1) non-peptide antagonists.
Polevaya L, Mavromoustakos T, Zoumboulakis P, Golic Grdadolnik S, Roumelioti P, Giatas N, Mutule I, Keivish T, Vlahakos DV, Iliodromitis EK, Kremastinos DT, Matsoukas J. Polevaya L, et al. Among authors: vlahakos dv. Bioorg Med Chem. 2001 Jun;9(6):1639-47. doi: 10.1016/s0968-0896(01)00059-1. Bioorg Med Chem. 2001. PMID: 11408184
80 results